MTOR and renal cell carcinoma: Based on the growing understanding of the underlying molecular pathways in RCC, the drugs targeting the PI3K/Akt/mammalian target of rapamycin (mTOR) have been discovered and evaluated in clinical trials, but their clinical efficacy is limited by resistance, toxicity, and poor tolerability (Guo et al., 2015).